Rigel to Present at Thomas Weisel Partners Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the
company's president and chief executive officer, is scheduled to present a
company overview at the Thomas Weisel Partners Healthcare Conference in
Boston, Massachusetts on Wednesday, September 3 at 10:20 a.m. EDT.
To access the live audio webcast or subsequent archived recording, log on
to http://www.rigel.com. Please connect to Rigel's website several minutes
prior to the start of the live webcast to ensure adequate time for any
software download that may be necessary.
About Rigel (http://www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and
develops novel, small-molecule drugs for the treatment of
inflammatory/autoimmune diseases and cancer, as well as viral and metabolic
diseases. Our pioneering research focuses on intracellular signaling pathways
and related targets that are critical to disease mechanisms. Rigel's
productivity has resulted in strategic collaborations with large
pharmaceutical partners to develop and market our product candidates. Rigel
has product development programs in inflammatory/autoimmune diseases such as
rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.
Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com
SOURCE Rigel Pharmaceuticals, Inc.

Ryan Maynard of Rigel Pharmaceuticals, Inc., +1-650-624-1284,
invrel@rigel.com